Efficacy of Carica Papaya Leaf Extract in Reducing Treatment-Delay Secondary to Chemotherapy induced Thrombocytopenia

Sreelatha, P.; Jose, Wesley

doi:10.7860/jcdr/2020/42582.13560

Cited by 3 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on published clinical evidence, overall, no major adverse reactions related to C. papaya leaf consumption were reported across a wide range of formulations, doses, and durations [ 5 , 6 , 32 – 50 ]. The most commonly reported side effects were gastrointestinal disturbances, comparable to control groups [ 5 , 37 , 39 , 41 , 50 ]. Cases of rash observed solely in the C. papaya -leaf-administered group of patients were also reported in two papers, highlighting a risk for allergic reactions [ 32 , 41 ] ( Table 4 ).…”

Section: Resultsmentioning

confidence: 99%

“…Thrombocytopaenia in dengue fever remains the most investigated indication of C. papaya leaf in clinical studies [ 6 , 32 – 41 , 43 , 48 – 50 ]. This is also reflected in the list of registered ongoing clinical trials ( S1 Table).…”

Section: Discussionmentioning

confidence: 99%

“…C. papaya leaves were mostly administered for a short duration of up to five days [ 6 , 32 – 34 , 36 , 37 , 39 – 44 , 48 , 49 ], though longer durations of administration have been reported to be tolerable [ 46 ]. Based on the published literature, mild gastrointestinal disturbances were most commonly reported [ 5 , 6 , 32 – 50 ]. Rash was reported in two papers in the C. papaya leaf juice and aqueous extracts intervention group solely [ 32 , 41 ].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Carica papaya L. Leaf: A Systematic Scoping Review on Biological Safety and Herb-Drug Interactions

Lim

Chan

Japri

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Introduction. The Carica papaya L. leaf is gaining interest as a potential therapeutic agent for alleviating dengue- and non-dengue-associated thrombocytopaenia. In that regard, safety considerations are as important as efficacy potential. The safety evaluation of botanical products for human use is complicated by variable formulations, complex phytochemical composition, and extrinsic toxicants. This review aimed to systematically collate related safety clinical and preclinical data, as well as reports on herb-drug interactions of C. papaya leaf consumption. Methods. A systematic search using predetermined keywords on electronic databases (MEDLINE, Cochrane Library Central, LILACS, and Web of Science) and grey literature was conducted. Relevant clinical and preclinical studies were identified, screened, and analysed to present an overall safety profile of C. papaya leaf consumption. Results. A total of 41 articles were included (23 clinical, 5 ongoing trials, and 13 preclinical) for descriptive analysis on study characteristics, adverse reactions, toxicity findings, and herb-drug interactions, from which 13 randomised controlled and quasiexperimental trials were further assessed for risk of bias and reporting quality. Overall, C. papaya leaf consumption (in the form of juice and standardised aqueous extract) was well tolerated by adult humans for short durations (<five days) while one randomised controlled trial reported safe consumption of C. papaya leaf standardised aqueous extract in children (aged 1–12 years). Minor gastrointestinal side effects were most commonly reported. There are concerns about hepatotoxicity and reproductive toxicity in long-term use, supported by animal studies. Unfavourable herb-drug interactions with metformin, glimepiride, digoxin, ciprofloxacin, and artemisinin were accounted. Conclusion. C. papaya leaf consumption in adults is generally safe for short-term use though cautioned in pregnancy and people with liver impairment. It has potential herb-drug interactions with oral hypoglycaemic agents, p-glycoprotein substrates, and antibiotics with cation chelating properties.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Carica papaya L. Leaf: A Systematic Scoping Review on Biological Safety and Herb-Drug Interactions

Lim

Chan

Japri

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…One theory is that CPLE contains papain which is a protease present in unripe papaya and CPLE. 9 Papain has many uses, including tenderizing meat and supporting digestion. Its properties and the mechanism for its action have been discussed in digestive research on Caricol ® , which is prepared with C. papaya .…”

Section: Discussionmentioning

confidence: 99%

“…2 CPLE has also been proven to reduce CIT-related delays in chemotherapy administration. 9 Additional studies on postchemotherapy populations have mirrored the results of these studies and have found no treatment-related adverse events; however, a recent review has reported that the most common side effect of CPLE use is minor gastrointestinal disturbance. 10,11 Recently, a case report of a neonate with persistent refractory thrombocytopenia concluded that CPLE treatment may even be applicable in this population.…”

Section: Introductionmentioning

confidence: 95%

A Case Study Using Papaya Leaf Extract to Reverse Chemotherapy-Induced Thrombocytopenia in a GBM Patient

et al. 2022

View full text Add to dashboard Cite

Chemotherapy-induced thrombocytopenia (CIT) is a critical condition in which platelet counts are abnormally reduced following the administration of chemotherapeutic compounds. CIT poses a treatment conundrum to clinicians given the increased risk of spontaneous bleeding, obstacles to surgical management of tumors, and exclusion from clinical trials. Treatment of CIT involves the removal of the offending agent combined with platelet infusion or thrombopoietin agonist treatment. However, due to the autoimmune and infection risks associated with infusions, this treatment is only reserved for patients with critically low platelet counts. One potential solution for patients in the mid to low platelet count range is Carica papaya leaf extract (CPLE). In this case, we report the novel use of CPLE as a method of bolstering platelet counts in a patient presenting with CIT. The patient was initiated on CPLE therapy consisting of 1 tablespoon twice daily with meals. Following CPLE treatment, the patient’s platelet counts rebounded from less than 10,000/µL to 113,000/µL. This clinical vignette supports the use of CPLE in the clinical context of CIT when thrombopoietin agonists are not a viable option. The potential benefits of CPLE as a method for increasing platelet count deserve further exploration, especially as a treatment option for refractory patients or those ill-suited for other traditional thrombocytopenia therapies.

show abstract

Delving into the Therapeutic Potential of Carica papaya Leaf against Thrombocytopenia

et al. 2022

View full text Add to dashboard Cite

Thrombocytopenia is a clinical manifestation that refers to the low platelet count, i.e., <150 × 103/μL, of blood, resulting in imbalanced hemostasis, which leads to several fatal complications. The causative factors vary greatly, but, as a consequence, they interfere with platelet production and promote destruction, leading to death. Carica papaya leaf has unique therapeutic and medicinal characteristics against thrombocytopenia, and this is supported by scientific studies. Secondary metabolites and minerals in the leaf, such as carpaine and quercetin, promote platelet production, inhibit platelet destruction, and maintain platelet membrane through gene expression activity and the ceasing of viral proteases, respectively. This review explores the scientific studies that support the role of papaya leaf in the form of juice, extract, or powder against thrombocytopenia through animal modeling and clinical trials. Phytochemical profiles of C. papaya leaf revealed the presence of flavonoids, alkaloids, phenols, cardiac glycosides, tannins, terpenes, and saponins, which impart therapeutic potential to the leaf. The therapeutic benefits of the leaf include immunomodulatory, antiviral, antidiabetic, anticancer, antimalarial, antiangiogenic, antibacterial, and antioxidant activities. Several conducted scientific research studies have proved the efficacy of C. papaya leaf against thrombocytopenia, expanding the implication of natural sources to eradicate numerous ailments.

show abstract

Efficacy of Carica Papaya Leaf Extract in Reducing Treatment-Delay Secondary to Chemotherapy induced Thrombocytopenia

Cited by 3 publications

References 0 publications

Carica papaya L. Leaf: A Systematic Scoping Review on Biological Safety and Herb-Drug Interactions

Carica papaya L. Leaf: A Systematic Scoping Review on Biological Safety and Herb-Drug Interactions

A Case Study Using Papaya Leaf Extract to Reverse Chemotherapy-Induced Thrombocytopenia in a GBM Patient

Delving into the Therapeutic Potential of Carica papaya Leaf against Thrombocytopenia

Contact Info

Product

Resources

About